Provided by Tiger Trade Technology Pte. Ltd.

BriaCell Therapeutics Corp. Warrant

0.0021
-0.0007-25.00%
Volume:56.86K
Turnover:126.04
Market Cap:3.69K
PE:0.00
High:0.0029
Open:0.0028
Low:0.0020
Close:0.0028
52wk High:0.2500
52wk Low:0.0017
Shares:1.76M
Float Shares:1.76M
Volume Ratio:0.98
T/O Rate:3.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-53.2836
ROE:-444.07%
ROA:-161.64%
PB:0.00
PE(LYR):- -

Loading ...

BRIEF-Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License

Reuters
·
Feb 19

Briacell and Briapro Enter Into Asset Purchase Agreement for Exclusive Soluble Cd80 License

THOMSON REUTERS
·
Feb 19

Briacell Therapeutics Corp - Briapro to Pay 2% Royalties to Umbc Upon Commercialization

THOMSON REUTERS
·
Feb 19

BRIEF-Briacell Therapeutics Announces Pricing Of $30 Million Public Offering At $5.59 Per Unit

Reuters
·
Jan 14

Briacell Therapeutics Corp - Units Sold at $5.59 per Unit for $30 Mln Gross Proceeds

THOMSON REUTERS
·
Jan 14

Briacell Therapeutics Announces Pricing of $30 Million Public Offering

THOMSON REUTERS
·
Jan 14

BRIEF-Briacell Phase 3 Trial Featured In Nature Medicine

Reuters
·
Dec 18, 2025

“Eleven Clinical Trials That Will Shape Medicine in 2026” – Briacell Phase 3 Trial Featured in Nature Medicine

THOMSON REUTERS
·
Dec 18, 2025

BRIEF-BriaCell's Phase 3 Patient Enrollment On Track For 1H2026 Topline Data Readout

Reuters
·
Dec 09, 2025

Briacell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

THOMSON REUTERS
·
Dec 09, 2025

Briacell Therapeutics Corp - Topline Interim Data Readout Expected in 1H2026

THOMSON REUTERS
·
Dec 09, 2025

BRIEF-Briacell And Receptor.Ai To Collaborate On Ai Driven Small Molecule Cancer Therapeutics

Reuters
·
Nov 20, 2025

Briacell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

THOMSON REUTERS
·
Nov 20, 2025

BRIEF-BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Reuters
·
Oct 22, 2025

Briacell Therapeutics Corp - Phase 3 Study Under FDA Fast Track Designation Being Conducted

THOMSON REUTERS
·
Oct 22, 2025